In this interview, Dr. Jason Coleman, Associate Director, Lipids & LNPs Platform at CordenPharma, discusses how the company’s integrated capabilities help customers advance LNP-based therapeutics from early development through clinical manufacturing. Drawing on CordenPharma’s long history in lipid development and manufacturing, he explains how expertise in customized lipids, targeting strategies, and nanoparticle design provides a strong foundation for supporting next-generation nanomedicines.
Jason highlights CordenPharma’s ability to work with a wide range of lipid technologies, including customized lipids, conjugated targeting approaches, and advanced LNP formulations. He also discusses collaborations focused on innovative delivery strategies, such as peptide-coated nanoparticles designed to target the tumor microenvironment. These capabilities enable customers to select and optimize the technologies best suited to their therapeutic applications while benefiting from specialized development and manufacturing support.
A key focus of the discussion is CordenPharma’s ongoing investment in LNP development and scale-up capabilities. The company has established a dedicated GMP facility for LNPs and received regulatory approval to manufacture a variety of nanomedicine products. Combined with multiple formulation technologies ranging from turbulent mixing to microfluidics, these investments provide customers with access to development and manufacturing solutions across different scales and stages of development.
Jason also explains the advantages of combining large-scale lipid manufacturing, LNP formulation expertise, and LNP starter kits within a single organization. Because lipid excipients play a critical role in nanoparticle performance, customers benefit from working with a partner that understands both the individual lipid components and the final drug product. This integrated approach supports analytical characterization, formulation development, process transfer, and GMP manufacturing, helping to reduce complexity and accelerate development timelines.
The interview concludes with a discussion of CordenPharma’s annual LNP event in Boston MA on Sept 22, 2026, which brings together experts from across industry and academia to explore the latest advances in lipid nanoparticle technologies, development strategies, and emerging applications. The event reflects CordenPharma’s commitment to fostering collaboration and advancing innovation within the rapidly growing LNP field.
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.